Astrazeneca chief ‘wants to shift London listing to US’ Markets The boss of Britain’s most valuable company, Astrazeneca, has reportedly voiced his preference to move the firm’s stock market listing to the United States. Sir Pascal Soriot, who has been at the helm of the pharma juggernaut since 2012, is said to have spoken privately about his desire to abandon the UK listing in favour [...]
Astrazeneca chief blasts Europe for ‘putting citizens’ health at risk’ healthcare Europe is putting its “ability to protect the health of its own people at risk” by not investing enough, the chief executive of FTSE 100 giant Astrazeneca has warned. Pascal Soriot added that the continent is “falling behind” in attracting R&D and manufacturing investment and needs to “invest more in what really matters to it”. [...]
Astrazeneca: ‘We’re too big to base our CEO’s pay on FTSE 100 peers’ Business Astrazeneca is too big and complex to base its chief executive’s pay packet on the rest of the FTSE index, according to the chair of its remuneration committee. Writing in the pharmaceutical giant’s annual report, chair Sheri McCoy said “UK-listed FTSE companies are not the right peer group for us to use” given the group’s [...]
Astrazeneca revenue surges amid Chinese import tax allegations February 6, 2025 Astrazeneca’s revenue jumped 21 per cent last year despite growing troubles over its presence in China. The pharmaceutical giant recorded $54bn (£43.3bn) in revenue for the year, a jump of 21 per cent on 2023’s levels. In its full-year results, the largest FTSE 100 firm revealed that revenue in Europe had skyrocketed 37 per cent. [...]
How Astrazeneca became the London Stock Exchange’s newest £200bn firm August 14, 2024 Astrazeneca has become the most recent UK-listed company to achieve a market valuation of £200bn, a landmark achievement for both the pharmaceutical giant and the London Stock Exchange, as investors have been won over by its ambition and success with cancer treatments. The company’s shares rose by 1.1 per cent on Tuesday, propelling its market [...]